Business Wire

FL-APPLIED-DATA-CORP

5.10.2021 16:03:10 CEST | Business Wire | Press release

Share
ADC Acquires Pinpoint Software, Continues to Expand Total Store Operations Platform

Applied Data Corporation (ADC), the global market leader for its SaaS-based total store operations platform built for retailers , today announced that it has entered into an agreement to acquire Pinpoint Software, Inc., a provider of software solutions driving operational efficiencies and execution for grocers and other retailers, including the world’s leading expiration date management platform, Date Check Pro® . The acquisition is a highly strategic addition to the ADC portfolio which includes ADC’s fresh item management platform, FreshIQ® , and fulfillment orchestration platform, ShopperKit, and will result in a solution that not only reduces food waste and delivers higher sales, but ultimately goes beyond sustainability to a more regenerative approach for retailers.

For most in the global retail space, food waste is a top concern that impacts the bottom line. As wasted food is the number one item going into landfills and contributing to GHG emissions, it is in everyone’s best interest to tackle this issue head-on. Both ADC and Pinpoint share a combined vision to arm retailers with the tools needed to drive sustainability results through a combination of quantification, analysis, and action.

“ADC’s trajectory as a total store operations platform continues to expand to meet the needs of retailers in today’s evolving market,” said Shamus Hines, CEO of ADC. “Pinpoint helps retailers proactively track inventory expiration dates across the store and work together with shoppers to minimize food waste.” Hines adds further, “As a company, we’re committed to enhancing all store operations for food retailers. With elevated consumer interest in sustainability, retailers are faced with the challenge to reduce food waste while also driving sales, and that is where both ADC and Pinpoint come into play.”

For nearly three decades, ADC has been a trusted provider to over 20,000 grocery and convenience store locations. The company’s SaaS platform of industry-tailored retail solutions already includes fulfillment orchestration, recipe management, made to order, label printing, inventory and waste management, food traceability, production planning, ordering, and temperature monitoring. With the addition of Pinpoint’s Date Check Pro , ADC will be able to offer additional reductions in shrink from expired products while also increasing customer satisfaction.

Andrew Hoeft, Founder and CEO of Pinpoint states, “At Pinpoint, we’ve always believed in driving efficiency and ensuring the freshest shopping experience possible for customers. ADC started in Fresh and has a strong belief in helping retailers reduce waste. Combined with our shared emphasis on user adoption with solutions that are easy to use and learn, joining forces with ADC was a perfect marriage. By blending our teams’ knowledge and solutions, we will continue to push the limits of retail operations technology.”

With this acquisition, work will immediately begin on an integration between the platforms in the coming weeks, the ADC website will be enhanced to show the full scope of the combined company.

About Applied Data Corporation

For more than 30 years, ADC has been a food technology innovator. Our platforms, FreshIQ® and ShopperKit, offer retailers an omnichannel approach to total store operations. FreshIQ allows retailers to effectively plan, prepare, analyze, and deliver the fresh food items shoppers want. The ShopperKit platform enables in-store order fulfillment for retailers to receive, prioritize, and process orders from their online counterparts allowing grocers to offer in-store pickup or delivery services to their online customers. ADC’s products are deployed globally in more than 120 grocery and convenience store chains and more than 20,000 locations. Visit www.applieddatacorp.com to learn more.

About Pinpoint

Pinpoint Software, Inc. is the parent company behind Date Check Pro. Founded in 2011 and based in the rapidly growing tech community and grocery tech hub of Madison, WI, Date Check Pro got its start when its founder Andrew Hoeft set out to solve the problem of expired shrink. Today, we help over a thousand supermarket, retail, and convenience store locations around the world eliminate their losses from dated and expired products and provide better products and experiences for their shoppers.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye